815 related articles for article (PubMed ID: 26362447)
1. Pro-Atrial Natriuretic Peptide: A Novel Guanylyl Cyclase-A Receptor Activator That Goes Beyond Atrial and B-Type Natriuretic Peptides.
Ichiki T; Huntley BK; Sangaralingham SJ; Burnett JC
JACC Heart Fail; 2015 Sep; 3(9):715-23. PubMed ID: 26362447
[TBL] [Abstract][Full Text] [Related]
2. Atrial and brain natriuretic peptides: Hormones secreted from the heart.
Nakagawa Y; Nishikimi T; Kuwahara K
Peptides; 2019 Jan; 111():18-25. PubMed ID: 29859763
[TBL] [Abstract][Full Text] [Related]
3. Roles of guanylyl cyclase--a signaling in the cardiovascular system.
Saito Y; Kishimoto I; Nakao K
Can J Physiol Pharmacol; 2011 Aug; 89(8):551-6. PubMed ID: 21671770
[TBL] [Abstract][Full Text] [Related]
4. Apparent B-type natriuretic peptide selectivity in the kidney due to differential processing.
Kishimoto I; Hamra FK; Garbers DL
Can J Physiol Pharmacol; 2001 Aug; 79(8):715-22. PubMed ID: 11558680
[TBL] [Abstract][Full Text] [Related]
5. Natriuretic peptides buffer renin-dependent hypertension.
Demerath T; Staffel J; Schreiber A; Valletta D; Schweda F
Am J Physiol Renal Physiol; 2014 Jun; 306(12):F1489-98. PubMed ID: 24717731
[TBL] [Abstract][Full Text] [Related]
6. Activation of myocardial and renal natriuretic peptides during acute intravascular volume overload in dogs: functional cardiorenal responses to receptor antagonism.
Borgeson DD; Stevens TL; Heublein DM; Matsuda Y; Burnett JC
Clin Sci (Lond); 1998 Aug; 95(2):195-202. PubMed ID: 9680502
[TBL] [Abstract][Full Text] [Related]
7. Evidence for Angiotensin II as a Naturally Existing Suppressor for the Guanylyl Cyclase A Receptor and Cyclic GMP Generation.
Ma X; Iyer SR; Ma X; Reginauld SH; Chen Y; Pan S; Zheng Y; Moroni DG; Yu Y; Zhang L; Cannone V; Chen HH; Ferrario CM; Sangaralingham SJ; Burnett JC
Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37239899
[TBL] [Abstract][Full Text] [Related]
8. Differing biological effects of equimolar atrial and brain natriuretic peptide infusions in normal man.
Hunt PJ; Espiner EA; Nicholls MG; Richards AM; Yandle TG
J Clin Endocrinol Metab; 1996 Nov; 81(11):3871-6. PubMed ID: 8923831
[TBL] [Abstract][Full Text] [Related]
9. Left ventricular assist device support reverses altered cardiac expression and function of natriuretic peptides and receptors in end-stage heart failure.
Kuhn M; Voss M; Mitko D; Stypmann J; Schmid C; Kawaguchi N; Grabellus F; Baba HA
Cardiovasc Res; 2004 Nov; 64(2):308-14. PubMed ID: 15485690
[TBL] [Abstract][Full Text] [Related]
10. Three molecular forms of atrial natriuretic peptides: quantitative analysis and biological characterization.
Nagai-Okatani C; Kangawa K; Minamino N
J Pept Sci; 2017 Jul; 23(7-8):486-495. PubMed ID: 28120499
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of TRPC6 channel activity contributes to the antihypertrophic effects of natriuretic peptides-guanylyl cyclase-A signaling in the heart.
Kinoshita H; Kuwahara K; Nishida M; Jian Z; Rong X; Kiyonaka S; Kuwabara Y; Kurose H; Inoue R; Mori Y; Li Y; Nakagawa Y; Usami S; Fujiwara M; Yamada Y; Minami T; Ueshima K; Nakao K
Circ Res; 2010 Jun; 106(12):1849-60. PubMed ID: 20448219
[TBL] [Abstract][Full Text] [Related]
12. β Cell-specific deletion of guanylyl cyclase A, the receptor for atrial natriuretic peptide, accelerates obesity-induced glucose intolerance in mice.
Tauscher S; Nakagawa H; Völker K; Werner F; Krebes L; Potapenko T; Doose S; Birkenfeld AL; Baba HA; Kuhn M
Cardiovasc Diabetol; 2018 Jul; 17(1):103. PubMed ID: 30016962
[TBL] [Abstract][Full Text] [Related]
13. Differential regulation of membrane guanylyl cyclases in congestive heart failure: natriuretic peptide receptor (NPR)-B, Not NPR-A, is the predominant natriuretic peptide receptor in the failing heart.
Dickey DM; Flora DR; Bryan PM; Xu X; Chen Y; Potter LR
Endocrinology; 2007 Jul; 148(7):3518-22. PubMed ID: 17412809
[TBL] [Abstract][Full Text] [Related]
14. Depressed Corin Levels Indicate Early Systolic Dysfunction Before Increases of Atrial Natriuretic Peptide/B-Type Natriuretic Peptide and Heart Failure Development.
Tripathi R; Wang D; Sullivan R; Fan TH; Gladysheva IP; Reed GL
Hypertension; 2016 Feb; 67(2):362-7. PubMed ID: 26667411
[TBL] [Abstract][Full Text] [Related]
15. Receptor selectivity of natriuretic peptide family, atrial natriuretic peptide, brain natriuretic peptide, and C-type natriuretic peptide.
Suga S; Nakao K; Hosoda K; Mukoyama M; Ogawa Y; Shirakami G; Arai H; Saito Y; Kambayashi Y; Inouye K
Endocrinology; 1992 Jan; 130(1):229-39. PubMed ID: 1309330
[TBL] [Abstract][Full Text] [Related]
16. Guanylyl cyclase / atrial natriuretic peptide receptor-A: role in the pathophysiology of cardiovascular regulation.
Pandey KN
Can J Physiol Pharmacol; 2011 Aug; 89(8):557-73. PubMed ID: 21815745
[TBL] [Abstract][Full Text] [Related]
17. The role of natriuretic peptides in cardioprotection.
Nishikimi T; Maeda N; Matsuoka H
Cardiovasc Res; 2006 Feb; 69(2):318-28. PubMed ID: 16289003
[TBL] [Abstract][Full Text] [Related]
18. N-terminal fragments of the proatrial natriuretic peptide in patients before and after hemodialysis treatment.
Franz M; Woloszczuk W; Hörl WH
Kidney Int; 2000 Jul; 58(1):374-83. PubMed ID: 10886584
[TBL] [Abstract][Full Text] [Related]
19. Molecular physiology of natriuretic peptide signalling.
Kuhn M
Basic Res Cardiol; 2004 Mar; 99(2):76-82. PubMed ID: 14963665
[TBL] [Abstract][Full Text] [Related]
20. Cenderitide: structural requirements for the creation of a novel dual particulate guanylyl cyclase receptor agonist with renal-enhancing in vivo and ex vivo actions.
Lee CY; Huntley BK; McCormick DJ; Ichiki T; Sangaralingham SJ; Lisy O; Burnett JC
Eur Heart J Cardiovasc Pharmacother; 2016 Apr; 2(2):98-105. PubMed ID: 27340557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
